Ketamine/esketamine in the treatment of depression with comorbid borderline personality disorder or traits: A systematic review of effectiveness
Australian & New Zealand Journal of Psychiatry September 20, 2025 Emma Scott, Don Thomas Thekkuden, Katelyn Kerr et al. 2 citations
A systematic review found that ketamine or esketamine may improve depression symptoms in people who also have borderline personality disorder. However, the available data are limited. Case reports describe suicidal ideation and self-harm after stopping treatment, and individuals with borderline personality disorder may face a higher risk of acute dissociation. Clinicians should therefore exercise caution when using ketamine for depression in this population. Larger randomized controlled trials are needed to better assess efficacy and side effects.